Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk NVO shares gained 2.7% on Thursday as investors focused on a major regulatory milestone for its obesity franchise, helping offset concerns stemming from NVO's disclosure of an IT security incident. The stock's advance reflected optimism around the U.K. Medicines and Healthcare products Regulatory Agency ("MHRA") approval of the Wegovy pill (oral semaglutide 25mg) for chronic weight management in adults with obesity or overweight and at least one weight-related condition. The therapy is indicated as an adjunct to a reduced-calorie diet and increased physical activity.

The approval makes the United Kingdom the first country in Europe to authorize a daily GLP-1 weight-loss pill, offering patients a convenient non-injectable alternative to weekly obesity treatments, with commercial availability via private prescription expected within weeks. In the United Kingdom, the drug is already approved as a once-weekly injection for reducing major cardiovascular events and easing HFpEF symptoms in obese patients.

Investors viewed the approval as strategically important, marking the third authorization for the Wegovy pill after the United States and the UAE. The oral therapy expands Novo Nordisk's obesity portfolio beyond injectable treatments, helping reach patients who are reluctant to use injections while offering the convenience of a daily pill and the potential for stronger treatment adherence. As the first approved daily GLP-1 weight-loss pill in Europe, the Wegovy pill strengthens Novo Nordisk's position in the fast-growing weight-management market, creating an additional avenue for future growth.

Year to date, NVO shares have lost 13.6% against the industry's 4.5% growth.Zacks Investment Research

Image Source: Zacks Investment Research

The positive regulatory news appeared to outweigh concerns about a cybersecurity incident disclosed by Novo Nordisk on the same day in a separate press release. The company reported unauthorized access to a limited number of internal IT systems and said certain non-public data, including personal information, had been copied externally without authorization. NVO has engaged external cybersecurity experts, notified relevant authorities and implemented containment measures, including temporarily taking some internal systems offline.

While the investigation remains ongoing and the incident could expose the company to regulatory scrutiny, remediation costs and reputational risks, Novo Nordisk stated that its core business operations have not been affected. The market's reaction suggests investors currently view the breach as a manageable operational issue, while assigning greater weight to the long-term commercial significance of Wegovy pill's landmark U.K. approval.

Story Continues

How Effective Is NVO's Wegovy Pill for Obesity?

The MHRA approval of Novo Nordisk's Wegovy pill was primarily based on robust late-stage clinical evidence from the phase III OASIS development program. The global program comprised four studies enrolling about 1,300 patients with obesity. A key 64-week phase IIIb study, OASIS 4, evaluated the efficacy and safety of the Wegovy pill compared to placebo in 307 adults with obesity or overweight with one or more comorbidities.

Results from OASIS 4 demonstrated strong and clinically meaningful weight loss, where obesity patients treated with the Wegovy pill achieved a mean reduction of 16.6% when treatment was adhered to. The magnitude of weight loss was comparable to that of injectable Wegovy 2.4 mg, with one in three patients achieving 20% or greater weight reduction. Importantly, the safety and tolerability profile of oral Wegovy was consistent with prior semaglutide studies, reinforcing confidence in its use. Novo Nordisk also noted that no currently available oral GLP-1 therapy matches the level of weight loss achieved with the Wegovy pill in clinical studies.

Per Novo Nordisk, obesity is a complex chronic disease affecting approximately 15 million people in the United Kingdom, with the prevalence of overweight and obesity among adults projected to reach 71% by 2040. The company emphasized that obesity requires long-term management and that treatment decisions, including the use of pharmacotherapy, should be tailored to individual patients through shared decision-making between healthcare providers and patients.

Novo Nordisk expects the approval and launch of the Wegovy pill in other select markets in the second half of 2026.

Novo Nordisk A/S Price and ConsensusNovo Nordisk A/S Price and Consensus

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote

NVO's Zacks Rank & Stocks to Consider

Novo Nordisk currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA, Indivior Pharmaceuticals INDV and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation's 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 107.7% year to date.

Liquidia Corporation'searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals' 2026 earnings per share have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV shares have gained 6.3% year to date.

Indivior Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore's 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.

Immunocore's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Novo Nordisk (NYSE:NVO) has received FDA approval for oral Wegovy, the first oral GLP-1 obesity treatment in the U.S. The company has begun the U.S. launch of oral Wegovy, aiming to broaden access to obesity treatment beyond injectable options. Novo Nordisk is highlighting longevity and aesthetics as future focus areas, building on research suggesting semaglutide may protect organs and reduce biological aging.

Novo Nordisk enters this new phase with oral Wegovy at a time when NYSE:NVO is priced around $43.96, after a period where the stock is down 16.1% year to date and down 44.0% over the past year. The longer term picture is mixed, with the stock down 42.8% over three years but up 14.5% over five years. This performance provides important context as investors consider the potential impact of this FDA approval and product launch.

For investors watching the obesity and diabetes space, oral Wegovy and the shift toward longevity and aesthetics could gradually reshape how Novo Nordisk is viewed, particularly as competition with Eli Lilly intensifies. Key questions now include how quickly oral adoption builds, how broad the health benefits of semaglutide prove to be, and how these developments influence investor expectations around NYSE:NVO over time.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.NYSE:NVO Earnings & Revenue Growth as at Jun 2026

We've flagged 3 risks for Novo Nordisk. See which could impact your investment.

The FDA approval and U.S. launch of oral Wegovy gives Novo Nordisk a new way to reach obesity patients who are reluctant to use injections, which can expand the addressable market rather than simply shifting existing users between formats. With more than 3,000,000 prescriptions written within just over five months, the pill is already showing that there is a large pool of patients who prefer an oral GLP-1 option. That scale matters as the company faces tougher competition from Eli Lilly and, to a lesser extent, Pfizer in weight management drugs. The early traction of oral Wegovy also supports Novo Nordisk's push to reposition semaglutide as a broader cardiometabolic and longevity platform, not only a weight loss drug. If future data on organ protection and biological aging translate into new indications in areas such as cardiovascular risk, liver health, or aesthetics, the revenue base could become less dependent on obesity alone. For now, investors are weighing this new growth channel and long-term optionality against weaker Wegovy momentum in some forecasts, pharmacy benefit manager decisions that currently favor Eli Lilly, and a 2026 outlook that includes expected pressure on sales and operating profit.

Story Continues

The Risks and Rewards Investors Should Consider

⚠️ Analysts point to competitive pressure from Eli Lilly and others, as some pharmacy benefit managers are currently favoring rival GLP-1 obesity treatments over Wegovy. ⚠️ Novo Nordisk's 2026 outlook includes projected declines in adjusted sales and operating profit, which could limit how much benefit investors see from new products if pricing or reimbursement tighten further. 🎁 The FDA approval and rapid uptake of oral Wegovy, with more than 3,000,000 U.S. prescriptions in just over five months, show strong patient demand for an oral obesity GLP-1 option. 🎁 Management's longevity and aesthetics focus, supported by research on semaglutide's potential organ protection and biological aging effects, opens possible new indication areas beyond obesity and diabetes.

What To Watch Going Forward

From here, keep an eye on oral Wegovy prescription trends and insurer coverage decisions, especially how large pharmacy benefit managers position oral GLP-1 drugs from Novo Nordisk versus Eli Lilly and other competitors. Watch for updates on semaglutide studies that test organ protection and longevity effects, since positive data in cardiovascular disease, liver conditions, or appearance-related indications could reshape long-term revenue mix. It is also worth tracking any revisions to sales and profit guidance as oral adoption, pricing, and competition evolve, because those signals show how much of this new growth path is flowing through to the financials.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Recent performance snapshot

Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with a gain of 2.7% over the past day contrasted with a decline of 6.5% over the past month.

See our latest analysis for Novo Nordisk.

Zooming out, Novo Nordisk's recent bounce comes after a softer patch, with the share price up over the past quarter but down year to date, while the 1 year total shareholder return is also lower. This suggests momentum has cooled compared with earlier periods.

If you are comparing Novo Nordisk with other healthcare opportunities, this is a good moment to see what else the market is pricing into 40 healthcare AI stocks

With the stock down 16.1% year to date and the latest close at US$43.96, the big question now is whether Novo Nordisk's current valuation still leaves upside on the table, or if the market is already pricing in future growth.

Most Popular Narrative: 53.7% Undervalued

According to the most followed narrative on Simply Wall St, Novo Nordisk's fair value of $95 sits well above the latest close of $43.96, pointing to a wide valuation gap.

"Valuation: We estimate fair value at ~$95 per ADR (base-case range $90–$100), reflecting a more competitive, more price-sensitive regime than the peak GLP-1 narrative, but also acknowledging the durability of the franchise and the expanding product/indication set."

Read the complete narrative.

Curious what kind of revenue profile, margins, and future earnings power have to line up to support that figure? The narrative stitches those assumptions together into a single, punchy fair value story that is very different from what the current share price implies.

Result: Fair Value of $95 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on key risks, including sustained pricing pressure and stronger GLP-1 competition, which could compress margins and challenge the fair value case.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

With sentiment split between concern over risks and optimism about rewards, this is the moment to look at the numbers yourself and decide how the trade off stacks up, starting with the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If Novo Nordisk has you thinking more carefully about price, risk, and quality, do not stop here. Broaden your watchlist with focused stock shortlists.

Story Continues

Target potential upside with 46 high quality undervalued stocks, where solid fundamentals meet prices that may not fully reflect underlying business strength. Prioritise resilience with 67 resilient stocks with low risk scores, highlighting companies that score well on financial stability and business risk checks. Get ahead of the crowd with screener containing 20 high quality undiscovered gems, a shortlist of companies with strong fundamentals that fewer investors are watching closely.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk (NVO) schloss bei $43,93 in der jüngsten Handelsitzung und markierte einen +2,62%iger Anstieg gegenüber dem Vortag. Der Aktienkurs übertraf den Tagesgewinn des S&P 500 um 1,75%. In der gleichen Zeit stiegen Dow und Nasdaq um 1,86 bzw. 2,54%. Die Aktie von Novo Nordisk fiel in den letzten Monat um 9,07% zurück, was unter dem Gesamtgewinn des Medical-Sektors (-3,73%) und dem Verlust des S&P 500 (-1,63%) lag. Investoren werden die Leistung von Novo Nordisk bei der kommenden Earnings-Erklärung genau beobachten. Bei dieser Erklärung wird ein Umsatz von $11,35 Milliarden erwartet, was einem Rückgang von 2,89% gegenüber dem entsprechenden Quartal des Vorjahres entspricht. Im Laufe des Jahres erwarten Analysten Earnings von $3,45 pro Aktie und einen Umsatz von $45,75 Milliarden. Diese Zahlen würden -12,88 bzw. -2,2% gegenüber dem Vorjahr darstellen. Investoren sollten auch die jüngsten Änderungen der Analystenschätzungen für Novo Nordisk beachten. Diese Revisionen spiegeln die neuesten kurzfristigen Geschäftsentwicklungen wider und können sich schnell ändern. Positiv veränderte Schätzungen deuten auf ein positives Geschäftswachstum und -rentabilität hin. Empirische Forschung zeigt, dass diese Änderungen der Schätzungen direkt mit zukünftigen Aktienkursentwicklungen zusammenhängen. Um dies auszunutzen, haben wir das Zacks-Ranking-System entwickelt, ein quantitatives Modell, das diese Änderungen und andere Faktoren berücksichtigt. Das Zacks-Ranking-System reicht von #1 (Strong Buy) bis #5 (Strong Sell) und hat eine beeindruckende Außenprüfung mit einer durchschnittlichen jährlichen Rendite von +25% seit 1988 aufgewiesen. In den letzten 30 Tagen ist unsere Konsens-EPS-Prognose um 0,49% gesunken. Aktuell trägt Novo Nordisk ein Zacks-Ranking von #3 (Hold). Im Bereich der Bewertung wird Novo Nordisk gegenwärtig bei einem Forward-P/E-Verhältnis von 12,41 gehandelt. Dieses Verhältnis markiert einen Rabatt im Vergleich zum Durchschnittswert des gesamten Industriesektors (15,3). Zudem verfügt NVO über ein PEG-Verhältnis von 3,83. Dieses Maß wird ähnlich wie das berühmte P/E-Verhältnis verwendet, aber es berücksichtigt auch die erwartete Earnings-Wachstumsrate. Der Large-Cap-Pharmazeutikasektor ist Teil des Medical-Sektors und hat derzeit einen Zacks-Industriewert von 83, was ihn in den Top 35% aller 250+ Industrien stellt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk (NYSE:NVO) is one of the top large cap value stocks to buy now. On June 8, Novo Nordisk presented Phase 3 results from its REIMAGINE 1–3 clinical program at the 2026 American Diabetes Association Scientific Sessions. The trials showed that the investigational treatment CagriSem, a once-weekly combination of an amylin analog and a GLP-1 receptor agonist, achieved significant, consistent reductions in both HbA1c levels and body weight across diverse groups of adults with type 2 diabetes.

This combination therapy leverages the synergistic effects of two distinct hormonal pathways to improve glucose regulation and appetite control. Novo Nordisk's Chief Scientific Officer, Martin Holst Lange, highlighted the therapy's potential to become a first-in-class treatment option, showing promise for patients at various stages of diabetes management, ranging from initial therapy to insulin add-on.Novo Nordisk (NVO): Top 10 Large Cap Value Stocks to Buy Now

The findings, simultaneously published in The Lancet and The Lancet Diabetes & Endocrinology, follow previous data from the REDEFINE program. By addressing multiple pathways of metabolic health, the REIMAGINE trials validate the clinical utility of pairing cagrilintide with semaglutide, offering a potential new strategy for patients who may require advanced approaches to managing their diabetes.

Novo Nordisk (NYSE:NVO) is a drug manufacturer for global pharmaceutical products that operates through two segments: Obesity & Diabetes Care and Rare Disease. The company was founded in 1923 and is headquartered in Denmark.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Novo Nordisk reported an IT security incident involving unauthorized access to internal systems. Certain non public, including personal, data was copied externally, prompting notifications to affected parties. Some IT systems were taken offline in response, while the company stated that business operations were unaffected.

Novo Nordisk, traded as CPSE:NOVO B, is addressing this cybersecurity incident against a backdrop of recent share price pressure. The stock closed at DKK281.2, with the price down 5.2% over the past 30 days and down 14.9% year to date. Over the past year, the share price has declined 43.3%, while the 5 year return stands at 21.4%.

For investors watching CPSE:NOVO B, the focus now is on how the company manages regulatory obligations, data protection efforts, and communication with stakeholders after the breach. The way Novo Nordisk strengthens its IT controls and restores confidence in its digital infrastructure may be an important factor for market perception going forward.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.CPSE:NOVO B 1-Year Stock Price Chart

Is Novo Nordisk's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.

The security incident lands at a sensitive time for Novo Nordisk, with the stock already under pressure and the company juggling heavy regulatory responsibilities across obesity and diabetes treatments. Because non public, including personal, data was copied externally, investor attention is likely to center on how regulators respond, whether any data protection authorities open formal investigations, and if this leads to fines or binding remediation orders in key markets. Even though management has said core operations remain up and running, temporarily taking systems offline often creates short term inefficiencies and extra spending on forensic work, remediation, and future prevention. For a global healthcare group handling clinical trial data, manufacturing systems, and patient support programs, repeated questions around IT security could eventually influence how doctors, partners, and regulators view its controls compared with peers such as Eli Lilly, Pfizer, or Roche. For you as an investor, the key issue is not just the one off incident, but whether this exposes structural weaknesses in cyber risk management that could translate into higher ongoing compliance costs and closer regulatory scrutiny over time.

Story Continues

How This Fits Into The Novo Nordisk Narrative

The incident reinforces the view that large global drug companies need strong risk and control frameworks to support long term growth in areas like GLP 1 therapies, especially as product and data footprints expand. It challenges expectations that Novo Nordisk can focus mainly on product execution without allocating more capital and management attention to cyber security, data governance, and compliance. The regulatory and legal consequences of this breach, including any penalties or mandated IT upgrades, may not be fully captured in high level discussions that focus on Wegovy, oral GLP 1 adoption, and pipeline progress.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Data copied externally raises the risk of enforcement action from privacy and data protection regulators, which could result in fines, formal reprimands, or ongoing monitoring obligations. ⚠️ Additional spending on cyber security, third party investigations, and potential legal claims could weigh on margins, adding to the 3 existing company level risks analysts have already flagged, including balance sheet and earnings quality concerns. 🎁 A prompt and transparent response, including notifying affected parties and authorities, may help limit reputational damage and demonstrate that governance structures are functioning under stress. 🎁 Investments made now to strengthen IT controls, if executed well, could reduce the likelihood and impact of future incidents, which may reassure long term focused investors who prioritize operational resilience.

What To Watch Going Forward

From here, keep an eye on updates about the incident scope, including whether any regulators open formal cases and how long key remediation work takes. Watch for commentary on additional cyber security spending in upcoming reports, as well as any disclosures about insurance coverage, legal claims, or settlements. It is also worth tracking how often Novo Nordisk reports on IT and data protection in its future filings and presentations, since more detailed disclosures can signal both higher risk awareness and potentially higher ongoing compliance costs.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO-B.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

This article first appeared on GuruFocus.

Novo Nordisk (NVO, Financials) and Eli Lilly face a new challenge as some U.S. employers reconsider coverage for GLP-1 weight-loss drugs.

Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.

The issue is cost. Even though prices for drugs such as Wegovy, Zepbound and Foundayo have come down, more people are using them. That means total spending for employers is still climbing.

A Business Group on Health survey found about 10% of employers that cover GLP-1 drugs for weight loss plan to drop coverage in 2027. Mercer found 5% of large employers are considering the same move.

For workers, this could mean paying out of pocket or using direct purchase programs offered by drugmakers. For employers, it reflects a difficult balance between offering popular health benefits and controlling medical costs.

For investors, the story is more complicated. Demand for GLP-1 drugs remains strong, but coverage limits could shape how fast the market grows.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

June 11 (Reuters) - Novo Nordisk said on Thursday it has ‌identified a security incident involving ‌unauthorized access to a limited number ​of internal IT systems.

The company said it has launched a probe with the assistance of external ‌cybersecurity experts, and ⁠are in contact with the relevant authorities.

The company ⁠has temporarily taken certain internal IT systems offline, and is ​working to ​bring the ​affected systems back ‌online in a controlled and safe manner.

"While our investigation and response are ongoing, we have discovered that certain non-public data, including ‌personal data, were copied ​externally without authorisation. ​We are ​informing the impacted parties ‌as appropriate," the Danish ​drugmaker ​said.

The company's core business operations are not impacted and remain ​up ‌and running, it added.

(Reporting by ​Sriparna Roy in Bengaluru; Editing ​by Shilpi Majumdar)

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk A/S

Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning of the incident, we launched an investigation with the assistance of external cybersecurity experts, and we are in contact with the relevant authorities.

As part of our response, multiple security measures have been taken, including temporarily taking certain internal IT systems offline to protect our environment. We are working to bring the affected systems back online in a controlled and safe manner; however, we acknowledge this process takes time.

Our core business operations are not impacted and remain up and running.

While our investigation and response are ongoing, we have discovered that certain non-public data, including personal data, were copied externally without authorisation. We are informing the impacted parties as appropriate.

Protecting the security and integrity of our systems and delivering reliable products and support to patients remain our highest priorities.

For more information about this incident, including privacy notifications, go to novonordisk.com.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Novo Nordisk Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 globalmedia@novonordisk.com Novo Nordisk Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com

Attachment

PR261106-IT-incident

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk A/S

Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semaglutide tablets will be available as a once-daily treatment, an alternative to weekly injections for adults living with obesity or overweight with a weight-related condition, alongside diet and exercise After this approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Novo Nordisk anticipates Wegovy® pill will be available via private prescription within weeks

Bagsværd, Denmark, 11 June 2026 – Wegovy® pill, the new daily weight management tablet, has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy® pill (semaglutide tablets), an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to <30 kg/m2), with at least one weight-related condition.

The MHRA approval is based on data from the OASIS 4 phase 3 clinical trial. When evaluating the effect of treatment regardless of adherence, adults with obesity receiving semaglutide tablets 25 mg achieved ~14% (13.6%) weight loss vs ~2% (2.4%) with placebo after 64 weeks, in addition to lifestyle modifications. Results showed that if all participants adhered to treatment, semaglutide 25 mg achieved weight loss of ~17% (16.6%) vs ~3% (2.7%) placebo after 64 weeks.

The study evaluated semaglutide tablets 25 mg in 307 adults with obesity or overweight with at least one weight-related condition, without diabetes. In the study, the most commonly reported side effects were gastrointestinal, including nausea, vomiting and diarrhoea, reported by 74.0% participants in the oral semaglutide group and by 42.2% in the placebo group, respectively. These side effects were generally mild to moderate and transient. In OASIS 4, adverse events leading to treatment discontinuation occurred in ~7% (6.9%) of participants receiving oral semaglutide, which is consistent with rates observed in trials of injectable semaglutide.

“This marks an important milestone for obesity care in the UK,” said Sebnem Avsar Tuna, general manager at Novo Nordisk UK. “For the first time, people living with obesity have access to a GLP-1 treatment in a daily pill, allowing them the choice and flexibility of oral treatment to support their long-term weight management.”

Story Continues

Professor Naveed Sattar, Professor of Cardiometabolic Medicine at the School of Cardiovascular & Metabolic Health at the University of Glasgow, said: "The approval of the once-daily oral form of Wegovy® (semaglutide) is welcome news for people living with obesity, particularly those who would prefer not to use injections. Expanding the range of effective treatments is important in helping people sustainably reduce caloric intakes within an increasingly obesogenic environment. With obesity rates in the UK now at very high levels, and associated with substantial multimorbidity, additional treatment options for sustained weight loss are greatly needed.”

“This is a landmark approval, making the UK the first country in Europe to approve Wegovy® pill,” said Emil Kongshøj Larsen, executive vice president, International Operations, Novo Nordisk. “Today, around 15 million people in the UK are living with obesity, yet only a small proportion of them have access to treatment, and we hope this approval supports increasing access to obesity care in the UK. With the introduction of this option for weight management, we have an opportunity to support many more eligible patients. Most importantly, this gives patients another option — one that may fit their lives and help them reach their health goals.”

Novo Nordisk has previously announced plans to launch Wegovy® pill in select markets in the second half of 2026. The MHRA is the third regulatory authority to license the medicine, after the U.S. Food and Drug Administration (FDA) and the United Arab Emirates, Emirates Drug Establishment (EDE).

OASIS 4 results The OASIS 4 trial included two pre-specified analyses: an on-treatment analysis assessing outcomes if all participants remained on treatment, and a treatment policy analysis reflecting outcomes regardless of treatment discontinuation.

About obesity Obesity is a complex, chronic disease affecting around 15 million people in the UK, with 71% of adults in the UK projected to be living with obesity or overweight by 2040. The condition requires long-term management. Treatment options should be individualised, with decisions about pharmacotherapy made jointly by healthcare professionals and patients.

About the OASIS 4 trial OASIS 4 was a randomised, double-blind, placebo-controlled phase 3 clinical trial evaluating the efficacy and safety of semaglutide 25mg tablets in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, without type 2 diabetes. The trial had two co‑primary endpoints: change in body weight (%) and the proportion achieving ≥5% weight loss at week 64. 307 participants were randomised 2:1 to receive semaglutide 25mg tablets or placebo once daily for 64 weeks in addition to lifestyle interventions. All participants received advice on diet and physical activity, including a daily 500 kcal deficit and a structured exercise regimen. The safety and tolerability profile for semaglutide 25 mg tablets in OASIS 4 was consistent with that observed for semaglutide injection. The most common adverse events were gastrointestinal, and the majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.

About Novo Nordisk Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. For more information, visitnovonordisk.com,Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Novo Nordisk Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 usmediarelations@novonordisk.com Novo Nordisk Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com

Attachment

PR2601106-UK-Wegovy-Pill-MHRA-Approval

View Comments